Selected publications
-
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
European Urology.
2020
Conference Paper
GET IT
Times cited: 1 -
Genomic correlates of clinical outcome in advanced prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America.
2019
Academic Article
GET IT
Times cited: 35 -
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (Nature Genetics, (2018), 50, 5, (645-651), 10.1038/s41588-018-0078-z).
Nature Genetics.
2019
Article
GET IT
Times cited: 1 -
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Journal of Clinical Investigation.
2018
Academic Article
GET IT
Times cited: 26 -
Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations.
Cancer Research.
2018
Academic Article
GET IT
Times cited: 13 -
The long tail of oncogenic drivers in prostate cancer.
Nature Genetics.
2018
Academic Article
GET IT
Times cited: 137 -
Expression of PD-L1 in hormone-naïve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 22 -
Impact of therapy on genomics and transcriptomics in high-risk prostate cance treated with neoadjuvant docetaxel and androgen deprivation therapy.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 25 -
Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 10 -
Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
Journal of Pain and Symptom Management.
2017
Academic Article
GET IT
Times cited: 7 -
A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy.
Journal of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 12 -
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
European Urology.
2016
Academic Article
GET IT
Times cited: 17 -
Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3.
Journal of Clinical Oncology.
2016
Conference Paper
GET IT
Times cited: 367 -
Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: The eyes have it!.
Histopathology.
2016
Academic Article
GET IT
Times cited: 3 -
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).
EBioMedicine.
2015
Academic Article
GET IT
Times cited: 8 -
A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Clinical Genitourinary Cancer.
2015
Academic Article
GET IT
Times cited: 22 -
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Clinical Cancer Research.
2015
Academic Article
GET IT
Times cited: 99 -
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 578 -
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study.
Journal of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 130 -
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Cancer Discovery.
2014
Academic Article
GET IT
Times cited: 189 -
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
European Urology.
2014
Academic Article
GET IT
Times cited: 179 -
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.
Nature Biotechnology.
2014
Academic Article
GET IT
Times cited: 329 -
Abiraterone in metastatic prostate cancer without previous chemotherapy.
New England Journal of Medicine.
2013
Academic Article
GET IT
Times cited: 1608 -
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Journal of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 358 -
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Cancer.
2009
Academic Article
GET IT
Times cited: 83